ArticleJournal of lipid research2025
Defective targeting of PNPLA1 to lipid droplets causes ichthyosis in ABHD5-syndromic epidermal differentiation disorder.
Article in Journal of lipid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Patatin-domain-containing (phospho)lipases under control: Mammalian co-regulators and pathogenic activation mechanisms.FEBS open bio · 2026Review
- Dysregulated cholesterol metabolism in genodermatoses: implications for systemic disease and therapeutic strategies.Frontiers in cell and developmental biology · 2026Review
- Specific organelle targeting as a key step in epidermal lipid synthesis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ABHD5-syndromic epidermal differentiation disorder (ABHD5-sEDD; also known as Chanarin-Dorfman syndrome) is a rare autosomal recessive disorder caused by mutations in the α/β-hydrolase domain-containing 5 (ABHD5) gene, leading to systemic accumulation of neutral lipids and ichthyosis due to impaired activation of patatin-like phospholipase domain-containing (PNPLAs) proteins. While ABHD5 is a well-known co-activator of adipose triglyceride lipase (ATGL, also referred to as PNPLA2), its role in epidermal lipid metabolism is incompletely understood. Here, we identify ABHD5 as a key regulator of PNPLA1, an enzyme essential for ω-O-acylceramide (acylCer) synthesis and skin barrier formation. We analyzed seven disease-associated ABHD5 missense mutations and found that they disrupt PNPLA1 localization and function by distinct mechanisms: (i) mutations affecting the PNPLA1 binding region of ABHD5 impair PNPLA1 recruitment to intracellular lipid droplets (LDs), thus reducing acylCer synthesis; (ii) mutations in potential perilipin-binding domains of ABHD5 prevent ABHD5 association with LDs, thereby disrupting PNPLA1-LD localization. Despite these defects, restoring co-localization of ABHD5 mutants with PNPLA1 in proteoliposomes rescued full PNPLA1 enzyme activity, indicating that spatial proximity rather than direct protein binding is sufficient to facilitate acylCer formation. In summary, our findings establish a co-localization-driven model of PNPLA1 regulation, in which ABHD5 ensures proper PNPLA1 targeting to LDs and simultaneously enables its enzymatic activation. This model suggests that pharmacological strategies aimed at restoring PNPLA1 localization to LDs may represent a potential therapeutic approach for ichthyosis in ABHD5-sEDD. By elucidating the molecular mechanisms underlying disease pathogenesis, our study provides important new insights into epidermal lipid metabolism and therapeutic targeting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.